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Promising new drugs are being evaluated for treatment of multiple
myeloma (MM), but their impact should be measured against the
expected outcome in patients failing current therapies. However,
the natural history of relapsed disease in the current era remains
unclear. We studied 286 patients with relapsed MM, who were
refractory to bortezomib and were relapsed following, refractory
to or ineligible to receive, an IMiD (immunomodulatory drug), had
measurable disease, and ECOG PS of 0, 1 or 2. The date patients
satisfied the entry criteria was defined as time zero (T0). The
median age at diagnosis was 58 years, and time from diagnosis to
T0 was 3.3 years. Following T0, 213 (74%) patients had a treatment
recorded with one or more regimens (median¼ 1; range 0–8). The
first regimen contained bortezomib in 55 (26%) patients and an
IMiD in 70 (33%). A minor response or better was seen to at least
one therapy after T0 in 94 patients (44%) including Xpartial
response in 69 (32%). The median overall survival and event-free
survival from T0 were 9 and 5 months, respectively. This study
confirms the poor outcome, once patients become refractory to
current treatments. The results provide context for interpreting
ongoing trials of new drugs.
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Introduction
Survival of patients with multiple myeloma (MM) has improved
during the past decade with the introduction of immunomodu-
latory drugs (IMiDs; thalidomide and lenalidomide), and the
proteasome inhibitor bortezomib.1–10 However, MM remains
incurable, and new therapies are required for continued disease
control. In fact, several new drugs are currently undergoing
evaluation, and many appear promising based on initial
results.5,11 One of the difficulties in interpreting the early results
of these newer therapies from the small single-arm studies has
been the lack of information about the natural history of MM in
the relapsed patient population. Although this type of informa-
tion is available for patients receiving the older therapies, such
data are lacking for patients relapsing after the new therapies.
This information can be beneficial for development of new
therapies, as early and accurate identification of the most
promising treatments can allow prioritization of current clinical
trials. Hence, the International Myeloma Working Group
(IMWG) undertook this current study with the aim of determin-
ing the outcome of patients who have become refractory to
bortezomib and at least one of the IMiDs. We also wanted to
assess the types of therapy administered in this patient group and
the response rates and duration of response to these treatments
to establish a context for assessing the results of ongoing trials
with new drugs in myeloma.
Patients and methods
Patients were identified by review of medical records at multiple
centers from across the United States, Europe and Asia. Patients
had to be refractory to bortezomib (administered either alone or
in combination with other agents), defined as no response (less
than partial response), or progression on therapy, or progression
within 60 days of stopping a bortezomib-containing regimen, as
per published consensus criteria. In addition, patients should
have relapsed and/or were refractory, intolerant or ineligible
(in the opinion of the treating physician) to receive treatment
with an IMiD (thalidomide or lenalidomide). We used either one
of the IMiDs instead of both IMiDs, taking into consideration the
differences in availability of the two drugs in different parts of
the world. The date the patient met this criteria was defined as
time zero (T0). Given the goal of using these data as a
benchmark for assessing future clinical trial results, we only
included patients who would typically be considered for
participation in a clinical trial. Hence, patients had to have
ECOG performance status of 0, 1 or 2, as well as measurable
disease at T0 (defined conventionally as a serum M protein
X1.0 g/dl or 24 h urine M-protein excretion X200 mg or bone
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marrow plasma cells X30%). Patients with prior allogeneic
stem cell transplantation were excluded from the study.
Clinical and laboratory data pertaining to the time of
diagnosis and from the time of individual relapses were obtained
from clinical records. The dates of initiation and discontinuation of
each treatment regimen, as well as the reason for discontinuation
were identified, with specific attention to confirmation of use and
discontinuation of IMiDs and bortezomib due to emergence of
resistance or toxicity. Detailed data collection sheets were devel-
oped, which were used at all the study sites for uniformity of data
collection. The data were sent to a centralized area (Cancer Research
And Biostatistics, Seattle, WA, USA) for analysis in a de-identified
manner. Institutional Review Boards from each site approved the
study and the use of patient medical records, and was conducted in
accordance with the principles of the Declaration of Helsinki.
Response categories were defined according to the EBMT or
IMWG criteria, and the response rate was defined as the
proportion of patients achieving at least a partial response, from
among those patients with valid response data. Patients who did
not receive a myeloma regimen following time zero were not
included in the response-rate analysis. The response rate and
best response were calculated for each regimen used before and
after T0. Duration of response was defined as the length of time
between the date a patient first achieved a partial response or
greater response level and the earlier of the dates at which
criteria for progression (defined by EBMT or IMWG criteria)
were met or the date of death. Patients who did not have a
documented progression after achieving at least a partial
response and who were still alive at last contact were censored
for duration of response at the date of last contact. Patients who
did not achieve a partial response or better following T0, and
patients for whom the date of such response was missing, were
excluded from the duration of response analysis. Duration of
response was estimated using the Kaplan–Meier method with
the median duration of response summarized.
Overall survival (OS) was defined as the length of time
between T0 and the date of death. Patients without a recorded
death date were censored for OS at their last contact date.
Progression-free survival (PFS) was defined as the length of time
between T0 until the earlier of the date at which criteria for
progression were met or the date of death. Patients who did not
have a documented progression after T0 and who did not have a
recorded death date were censored for PFS at their last contact
date. OS and PFS were estimated using the Kaplan–Meier
method with the median survival durations summarized. Cox
regression analysis was performed to determine which prog-
nostic factors at T0 and/or at baseline correlated with improved
OS or PFS from T0. Prognostic factors were dichotomized,
where appropriate, using standard myeloma cutoffs. Prognostic
factors with univariate P-values o0.100 were considered for
inclusion in the multivariate model. The multivariate model
used a stepwise selection with an entry level of Po0.10; with
backwards elimination set at Po0.05.
Time to next treatment (TNT) after T0 was defined as the
length of time between the start of the first regimen following T0
and the start of the second regimen following T0. Patients who
started both a first and second regimen following T0, who do not
have recorded start dates for these regimens, were excluded
from this analysis. Patients who did not start a second regimen
following T0 were censored for TNT at the date of last contact.
TNT was estimated using cumulative incidence methodology,
with the median TNT summarized. Death preceding the start of
a second regimen following T0 was treated as a competing risk.
Additional TNT estimates were generated for subsequent regi-
mens where a sufficient number of patients have recorded start
dates for the required treatment regimens. All analyses were
carried out using SAS version 9.1.3.
Results
Complete data were available on 286 patients (from among 300
patients enrolled) and were included in the current analysis. This
included patients from nine sites (107 patients from three US
sites; 115 from five European sites; and 64 from one Asian site).
The median (range) age for the patient group was 58 years
(30–85) at diagnosis and 62 (35–87) at time zero, and 176 (62%)
were male. The median estimated follow-up for the entire
cohort from diagnosis was 5.8 years (95% CI; 5.1, 6.3) and
the median time from diagnosis to T0 was 3.3 years (range,
0.2–18.7). The baseline characteristics from diagnosis and from
T0 are as shown in Table 1. The median number of regimens
Table 1 Baseline characteristics at diagnosis and at time zero (T0)
Factor N/n (%)
Male 176/286 (62)
Median age at diagnosis (range) 58 (30–85)
Serum heavy chain at diagnosis
None 27/250 (1)
IgG 155/250 (62)
IgA 60/250 (24)
Durie Salmon stage at diagnosis
Stage 1 14/216 (6)
Stage 2a 47/216 (22)
Stage 3a 152/216 (70)
ISS at diagnosis
Stage 1 63/208 (30)
Stage 2 87/208 (42)
Stage 3 58/208 (28)
Diagnosis Creatinine 4 ULN 84/212 (40)
No bone lesions at diagnosis 63/256 (25)
X4 bone lesions at diagnosis 102/256 (40)
Diagnosis FISH
All abnormalities 63/95 (66)
del 17p, t(4;14), t(14;16) 21/95 (22)
13q- 41/95 (43)
t(11;14) 9/95 (9)
Diagnosis cytogenetic abnormalities 50/132 (38)
Time zero (T0)
Median age at T0 (range) 62.5 (35–87)
ISS at T0
Stage 1 31/172 (18)
Stage 2 82/172 (48)
Stage 3 59/172 (34)
FISH at T0
All abnormalities 30/38 (79)
del 17p, t(4;14), t(14;16) 9/38 (26)
13q- 13/38 (34)
t(11;14) 3/38 (8)
T0 cytogenetic abnormalities 23/47 (49)
Median number of regimens before T0 (range) 4 (1,13)
At least 1 transplant before T0 178/286 (62)
X2 transplants before T0 42/286 (15)
Abbreviations: FISH, fluorescence in situ hybridization; ISS, International
staging system; n, number with factor; N, number with valid data for factor.
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before T0 was 4 (range, 1–13); 81 (41%) patients had three
regimens or less before reaching T0 and 45 (16%) patients had
received 46 regimens by the time they reached T0. The details of
the initial therapy in terms of the drugs used are included in
Supplementary Table 1. In terms of prior therapy, by definition all
patients had previous therapy with bortezomib and were
considered refractory to bortezomib. Among them, 188 patients
had relapsed on therapy while the remaining patients had either
not responded or had relapsed within 60 days of discontinuing the
drug. With respect to the IMiDs, 205 and 79 patients, respectively,
were refractory to or ineligible for treatment with thalidomide or
lenalidomide. Among the thalidomide treated patients, 135
patients had relapsed on therapy and/or were refractory, 69
patients had gone off for toxicity and were considered as
intolerant, and one person was missing this information. For the
lenalidomide patients, 70 had relapsed on therapy and/or were
refractory, and nine were intolerant. The drug that patients were
relapsing on or refractory to immediately before (or closest to) T0
was bortezomib in 73% and an IMiD in 27%.
Initial therapy following time zero
We first examined the types of therapy that were used
immediately following T0. Only 213 patients (74%) had a
treatment identified in the medical records following T0 and the
median time to first treatment following T0 was 0.5 months. The
drugs used (alone or in combinations) for the initial treatment of
the relapsed refractory disease are detailed in Table 2. Interest-
ingly, in this group of patients who met the criteria for having
bortezomib refractory disease, 55 patients (26%) received a
bortezomib-containing treatment regimen immediately follow-
ing T0. Bortezomib alone or with dexamethasone was the most
common bortezomib-based regimen used (41%) followed by the
combination of bortezomib, lenalidomide or thalidomide, and
dexamethasone (17%). Thalidomide or lenalidomide was
included in the initial treatment in 70 patients (32%). As would
be expected, corticosteroids were part of the treatment in 157
(74%) patients, including 17 (8%) patients receiving steroids as
single agents. Alkylating agents (melphalan and cyclopho-
sphamide) was the most common class of drugs used at this
stage of the disease with 97 (46%) patients receiving a regimen
that contained one of these drugs. Interestingly, 22 (11%) and 25
(12%) of patients received cisplatin and etoposide, respectively,
likely a reflection of the use of regimens such as DT-PACE.
Nearly a quarter of patients achieved a partial response or
better to the first regimen used after T0 (50/213, 24%) including
a very good partial response or better in 7% of the patients.
Another 22 (7%) patients had a minor response and 36 (10%)
had stable disease as their best response to the treatment. Nearly
half of the patients (104; 49%) had progressive disease to the first
line of therapy following T0 or a response was not assessable.
The response rates and categories of responses observed are as
detailed in Table 3. We also analyzed responses by regimen,
based on whether patients received a regimen containing the
newer drugs (bortezomib, lenalidomide or thalidomide) or not.
The response rate to the first treatment regimen was 24% among
the 106 patients treated with a regimen containing bortezomib,
lenalidomide or thalidomide compared with 25% among the
107 patients receiving a regimen not containing one of these
three drugs (Table 3). Specifically, 12 (22%) of the 55 patients
receiving bortezomib as part of the first regimen after T0 had a
response of partial response or better. The breakdown of the
response rates and the response categories for a newer drug-
containing regimen and those without these three drugs is
provided in Supplementary Tables 2–4. The primary reasons
for discontinuing the regimens are detailed in Supplementary
Table 5. The most common reason for discontinuation of a
treatment regimen was lack of response or disease progression
followed by adverse event or completion of planned course of
treatment. A clear reason for discontinuation could not be
ascertained for about 17% of the regimens.
Subsequent therapies
The subsequent drugs used for treatment within the different
lines of therapy are detailed in Table 2, along with the best
Table 2 Response rate by regimen number, following time zero (T0)
Drugs included in the regimen Regimen number following time zero (T0)
1 2 3 4 5
Number of patients 213 90 49 27 18
Corticosteroids (part of combination) 140 (66) 47 (52) 26 (53) 20 (74) 9 (50)
Cyclophosphamide 66 (31) 22 (24) 10 (20) 6 (22) 3 (17)
Bortezomib 55 (26) 22 (24) 19 (39) 7 (26) 8 (44)
Doxorubicin 43 (20) 11 (12) 6 (12) 1 (4) 3 (17)
Lenalidomide 41 (19) 13 (14) 8 (16) 6 (22) 3 (17)
Melphalan 31 (15) 15 (17) 9 (18) 7 (26) 0 (0)
Thalidomide 29 (14) 15 (17) 7 (14) 3 (11) 2(11)
Etoposide 25 (12) 4 (4) 3 (6) 0 (0) 2 (11)
Cisplatin 22 (10) 6 (7) 3 (6) 0 (0) 2 (11)
Corticosteroids alone 17 (8) 6 (7) 2 (4) 1 (4) 0 (0)
Vincristine 18 (8) 3 (3) 2 (4) 2 (7) 1 (6)
BCNU (Carmustine) 4 (2) 1 (1) 2 (4) 1 (4) 0 (0)
Best response (XPR) (%) 50/213 (24) 17/90 (19) 12/49 (24) 6/27 (22) 1/18 (6)
Best response (XMR) (%) 73/213 (34) 25/90 (28) 14/49 (29) 8/27 (30) 3/18 (17)
Best Response with a regimen
containing bortezomib, lenalidomide
or thalidomide, % (number of patients)
25/106 (24) 6/42 (14) 7/27 (26) 1/14 (7) 0/10 (0)
Best Response with a regimen without
bortezomib, lenalidomide or thalidomide,
% (number of patients)
26/107 (24) 11/48 (23) 5/22 (23) 5/13 (38) 1/8 (13)
Median duration of treatment (months) 1.9 1.3 1.4 1.7 1.9
Abbreviations: MR, minor response; PR, partial response.
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responses by regimen number (for the first five regimens) in
Table 3. The median TNT following the first regimen after T0
was 0.5 months. Interestingly, bortezomib and the IMiDs
continued to be used in the subsequent regimens in a significant
proportion of patients. Overall, 75 (35%), 51 (24%) and 63
(30%) patients received bortezomib, thalidomide or lenalido-
mide at some point after T0. The breakdown of the response
categories for the newer drug-containing regimen and those
without these three drugs are provided in Supplementary Tables
2 and 3. Overall, 94 (44%) of patients had a minimal response
or better including a partial response or better in 69 (32%)
patients at some point during the post T0 period. The median
times to achieving any degree of response are shown in Figure 1.
The primary reasons for discontinuing the regimens are detailed
in Supplementary Table 5 (Supplementary data).
We also examined the frequency of use of high-dose therapy
and stem cell transplantation in this population. There were 44
patients who received a transplant after time zero, the median
time to transplant was 96 days (B3 months) with the first
transplant received after 5 days and the last one received after
936 days (B2 years and 5 months). Half of the patients who
received a transplant after T0 received it between 37 days and
203 days. Among the 44 patients receiving a transplant after T0,
this was the first transplant in 16 patients (that is, no transplants
were carried out before T0).
Survival outcomes
The median event-free survival for the entire cohort was
5 months (95% CI; 4, 6) from T0 and the median OS was
9 months (95% CI; 7, 11) from T0 (Figure 2). The overall survival
from diagnosis for the entire cohort was 56 months (95%
CI; 44, 72). The median OS for the 213 patients who received
at least one regimen after T0 was 12 months (95% CI; 10,14),
and for the remaining patients it was 3 months (95% CI; 2,3).
We also examined the OS from T0 based on whether the
patients first met criteria for bortezomib refractoriness or the
IMiD criteria for inclusion in the study. The median OS from
T0 was 9 months (95% CI; 7,11) for patients meeting
the bortezomib criteria first, similar to 9 months (95% CI;
7,13) for patients meeting criteria for IMiDs first (P¼ 0.44). We
also separately examined the outcome from the date they
became refractory to bortezomib. The median OS from the
time they were considered refractory to bortezomib (as
defined for the purposes of the study) was 11 months (95%
CI; 10,14). Similarly, the median OS from the date patients
were considered to be relapsed/refractory/ineligible to an
IMiD was 22 months (95% CI; 15, 26) for lenalidomide patients
and 16 months (95% CI; 14, 22) for thalidomide patients. We
further examined the outcome based on whether the patients
received the alternate IMiD. The median OS for lenalidomide
refractory patients receiving thalidomide for salvage was 8
months and for thalidomide refractory patients receiving
lenalidomide was 12 months from the start of the second
IMiD, with the analysis landmarked at the start of the alternate
IMiD. The median OS from the time they were refractory to any
Table 3 Best response to regimen, by regimen number, for the initial regimens following time zero
Regimen 1st 2nd 3rd 4th 5th
factor
Number of patients 213 90 49 27 18
Complete response (%) 4/213 (2) 1/90 (1) 0/49 (0) 1/27 (4) 0/18 (0)
Very good partial response (%) 10/213 (5) 2/90 () 1/49 (2) 2/27 (7) 0/18 (0)
Partial response (%) 36/213 (17) 14/90 (16) 11/49 (22) 3/27 (11) 1/18 (6)
Minor response (%) 22/213 (10) 8/90 (9) 3/49 (6) 2/27 (7) 2/18 (11)
Stable disease (%) 36/213 (17) 16/90 (18) 8/49 (16) 6/27 (22) 4/18 (22)
Progression (%) 48/213 (23) 25/90 (28) 15/49 (31) 5/27 (19) 3/18 (17)
No or Unknown response (%) 56/213 (26) 24/90 (27) 11/49 (22) 8/27 (30) 8/18 (44)
n/N (%): n, number with factor; N, number with valid data for factor.
Figure 1 Figure shows the time to response at any time after time
zero (T0) for the different categories of responses among 213 patients
who received at least one treatment after T0.
Figure 2 Figure shows the Kaplan–Meier curves for event-free
survival (red curve, median 5 months) and overall survival (blue
curve, median 9 months) from T0 for all patients (n¼ 286) enrolled on
the study.
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one of the novel agent (bortezomib or IMiD) was 10 months
(95% CI: 7,14).
The per regimen outcome of patients on this study is detailed
in Supplementary Table 6, which provides patient disposition
data in terms of treatment status and survival at various time
points from T0. The numbers of patients in each successive
treatment regimen who died during that regimen, received
another treatment, or are still receiving that regimen are shown
in the table.
Prognostic factors
We performed additional analyses to identify prognostic factors
predicting event-free survival and OS following T0. Factors
impacting the OS and event-free survival from T0 identified
in a univariate analysis are shown in Table 4. In a multivariate
model using stepwise selection that included most of these
variables only B2M45.5 mg/l at T0 (HR: 3.58; P¼ 0.047) and
albumin o3.5 mg/dl at T0 (HR: 5.62; P¼ 0.009) were indepen-
dently significant for OS. Given that B2M and serum albumin,
the two components of ISS, was prognostic for survival in this
patients group, we examined the outcome based on ISS stage at
T0. As shown in Figure 3, the ISS stage was prognostic for overall
survival following T0, with median survivals of 12, 8 and 4
months for ISS stages 1, 2 and 3, respectively. However, the ISS
stage did not predict event-free survival in this group.
Given that nearly 20% of the patients survive beyond 2 years,
we specifically compared the baseline characteristics of those
who survived beyond 2 years to those who died within 3 months
of reaching T0. The results of the comparison, which is detailed
in Supplementary Table 7, demonstrated significant differences
between the two groups in terms of lower B2M and fewer
patients with ISS stage 3 both at diagnosis and at T0, normal
creatinine at T0, and at least a partial response or better before
T0 among the group with longer survival.
Discussion
New developments in therapy over the past decade have
changed the treatment paradigm for myeloma and resulted in
significant improvement in survival.9,10,12 However, myeloma
remains incurable and new treatments are currently being
studied. The results of the new drugs, especially those from the
single-arm trials, should be interpreted in the context of the
expected outcomes in this group of patients. However, the rapid
pace of development in the area of myeloma therapy has
precluded a good understanding of the outcome among patients
who have exhausted the currently available therapies. The
natural history of relapsed myeloma has been studied pre-
viously, but before the new drugs became available. Specifi-
cally, one study included 578 patients with newly diagnosed
Table 4 Univariate analysis of prognostic factors for OS and EFS from T0
Variable n/N (%) OS from time zero EFS from time zero
HR (95% CI) P-value HR (95% CI) P-value
At Diagnosis
Serum heavy chain: None 27/250 (11) 1.73 (1.03, 2.89) 0.038 1.51 (0.94, 2.42) 0.085
Serum heavy chain: G 155/250 (62) 0.62 (0.45, 0.86) 0.005 0.68 (0.51, 0.91) 0.010
Serum heavy chain: A 60/250 (24) 1.40 (0.98, 2.01) 0.064 1.27 (0.92, 1.76) 0.148
B2MX3.5 mg/l 123/226 (54) 1.59 (1.12, 2.26) 0.009 1.58 (1.15, 2.16) 0.004
Plateleto150 000/ml 50/229 (22) 1.57 (1.06, 2.32) 0.024 1.20 (0.83, 1.72) 0.325
FISH t(4;14) 9/95 (9) 2.14 (0.90, 5.10) 0.086 2.15 (0.97, 4.74) 0.058
Hypodiploidy 14/132 (11) 1.86 (1.01, 3.41) 0.045 1.53 (0.85, 2.77) 0.158
At Time zero
AgeX65 year 115/284 (40) 1.34 (0.98, 1.82) 0.063 1.11 (0.84, 1.46) 0.471
Serum heavy chain: None 23/176 (13) 1.86 (1.10, 3.14) 0.021 1.50 (0.91, 2.46) 0.114
Serum heavy chain: G 108/176 (61) 0.49 (0.33, 0.74) o0.001 0.58 (0.41, 0.83) 0.002
Serum heavy chain: A 41/176 (23) 1.69 (1.09, 2.61) 0.020 1.54 (1.04, 2.27) 0.029
Albumino3.5 g/dl 152/279 (54) 1.73 (1.26, 2.37) o0.001 1.47 (1.12, 1.93) 0.006
B2MX3.5 mg/l 108/173 (62) 2.36 (1.55, 3.60) o0.001 1.71 (1.20, 2.44) 0.003
B2M45.5 mg/l 59/173 (34) 2.20 (1.50, 3.25) o0.001 1.55 (1.09, 2.21) 0.015
ISS Stage 3 59/172 (34) 2.24 (1.52, 3.31) o0.001 1.57 (1.10, 2.24) 0.013
Creatinine4ULN 64/185 (35) 2.19 (1.48, 3.25) o0.001 1.50 (1.06, 2.11) 0.022
FISH t(14;16) 3/38 (8) 5.04 (0.97, 26.16) 0.054 2.43 (0.54, 10.98) 0.250
Time zero cytogenetic abnormalities 23/47 (49) 3.71 (1.43, 9.66) 0.007 1.82 (0.93, 3.55) 0.080
Time zero hypodiploidy 12/47 (26) 3.57 (1.52, 8.38) 0.003 3.77 (1.72, 8.27) o0.001
At least 1 transplant before time zero 178/286 (62) 1.17 (0.85, 1.61) 0.331 1.29 (0.98, 1.71) 0.072
Abbreviations: CI, confidence interval; EFS, event-free survival; FISH, fluorescence in situ hybridization; HR, hazard ratio; OS, overall survival.
P-value from Wald Chi-square test in cox regression.
Figure 3 Figure shows the overall survival from T0 by ISS stage at T0.
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MM who were followed up and monitored throughout their
clinical course at a single institution between 1985 and 1998.13
The OS for the 578 patients at 1, 2 and 5 years was 72%, 55%,
and 22%, respectively; the median OS from initial therapy was
28.4 months. The median OS of 355 patients who had relapsed
at the time of the analysis was 17.1 months from initiation of the
second therapy, and 84% died within 5 years. This study
revealed decreasing response duration with increasing number
of salvage regimens, likely reflecting acquired drug resistance.
The median survival of patients who had three previous
therapies in the initial trials of bortezomib for similar patients
was 12 months compared with the 5 months seen in that study
demonstrating clinically relevant activity for the drug.14
Similarly, the overall survival of heavily pre-treated patients in
the initial study of thalidomide demonstrated a 58% overall
survival at 12 months, again demonstrating improvement over
historical data.15 However, with the improved survival due to
the widespread use of IMiDs and bortezomib these data are no
longer reflective of the current practice.
It is important to understand the clinical course of patients,
who have become refractory to one or more of these agents and
hence our study was focused on patients considered refractory
to bortezomib and at least one of the IMiDs. However, these
drug scan be used in combination with a variety of agents,
giving rise to multitude of regimens and detailed information
regarding the specific combinations these drugs were part of is
not available. In the current study, we specifically enrolled
patients who would be considered eligible for a clinical trial, by
restricting to patients with good performance status and those
with measurable disease at the point at which they would be
considered refractory to bortezomib and to one of the IMiDs.
The definitions for refractory disease were based on the
recommendations of the ASH/FDA Panel on clinical endpoints
in myeloma.16 Patients eligible for clinical trials generally have
better survival outcomes irrespective of diseases being
studied17,18 which does limit the generalizability of the results
to the myeloma patient population as a whole; but at the same
time allows better comparison with the current clinical trials.
We also only required failure of either one of the IMiDs to be
eligible for the study, taking into account the varied availability/
accessibility of the two drugs in different parts of the world. By
incorporating patients from several large centers from different
geographical regions, similar to what is often seen in the large
multicenter trials, we hoped to overcome the effect of
heterogeneity of clinical practice. By using a uniform approach,
we have therefore sought to minimize the heterogeneity
in reporting that can happen in a multicenter study.19,20
One of the most striking findings in our study has been the
response rates seen in this patient population with the first
regimen used after they become refractory to the new drugs. The
overall response seen in a third of the patients can be due to
several factors. With the advent of the new drugs, older drugs
such as alkylators are increasingly being relegated to later stages
of disease. It has been shown in the setting of transplant, that
patients relapsing after IMiD therapy can obtain comparable
response duration with delayed transplant as with early
transplant suggesting preservation of sensitivity of tumor cells
to alkylators.21 In fact, alkylators were the most common drugs
used for treatment of patients once they stopped responding to
the newer drugs in the current study. In addition, transplant is
increasingly being used later in the disease course, as is second
transplants as salvage therapy. In fact in the current study nearly
20% of patients received a transplant after T0, a third of which
were first time transplants. Finally, many of the new drugs can
be used again in patients who initially responded but had
stopped responding to it, with variable degrees of responses.22
Bortezomib has activity with retreatment 22–25 and lenalidomide
has significant activity in thalidomide refractory population.6 As
in this study, many of the current clinical trials include a similar
mix of patients and the response rates seen in these phase 2 trials
and in phase 3 trials utilizing standard of care for the control arm
should be considered in the context of these findings. In contrast
to previous studies, we do not see a progressive decline in
response rates and duration of response.13 This may be a
reflection of increasing treatment choices that are available
compared with a decade ago when alkylating agents and
steroids formed the basis of myeloma treatment.26 Also, some
degree of selection bias leading to patients with better
performance status, as well as patients with more indolent
disease being considered for multiple therapies cannot be
excluded.
Despite the initial responses of over 30% in this group of
relapsed and refractory patients, the median event-free survival
of 5 months and OS of 9 months highlight the limited durability
of these responses and the poor overall outcome among patients
who are no longer responding to the existing newer therapies.
This is consistent with recent reports showing the poor outcome
of patients refractory to IMiDs even in the context of stem cell
transplantation.27 Another important finding from the study was
the continued value of conventional prognostic factors in this
patient group. Interestingly, the ISS staging parameters B2M
and serum albumin at T0 best predicted survival outcome in this
group of patients and should be taken into account when
comparing results between different trials. They could in fact be
incorporated as stratification factors in clinical trials of new
drugs.28 Unfortunately, limited data were available with respect
to cytogenetic and fluorescence in situ hybridization features in
the current study. However, examination of the available data
suggests retained prognostic value for these characteristics.
Patients with high-risk genetic abnormalities such as t(4;14),
t(14;16) and hypodiploidy had shorter duration of responses and
poorer OS compared with the other patients.29–31 As has been
seen in previous studies in the context of newly diagnosed
disease, the presence of renal insufficiency predicted poorer
survival. This might to some extent reflect the lack of enrollment
in clinical trials of patients with compromised renal function.
Clearly the results presented here have some drawbacks,
particularly the inability to study patients who are refractory to
individual IMiDs, the prognostic value of all genetic risk factors
in the context of specific therapies and the variations across
different geographical areas based on clinical practices and drug
availability. An ongoing study is recruiting additional patients to
extend the current analyses.
In conclusion, the current study provides valuable insights
into the natural history of myeloma after it become non-
responsive to the novel therapies. Clearly there are some
disadvantages with the current study, such as the inclusion of
only ‘trial eligible’ patients and the lack of uniform availability
of modern prognostic factors such as cytogenetic and fluores-
cence in situ hybridization abnormalities. However, the results
provide an important reference point for comparison of the
results of the ongoing phase 2 and possibly phase 3 trials of new
drugs in myeloma.
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